Bone Biologics Corp Stock Current Valuation

BBLG Stock  USD 1.52  0.06  4.11%   
Valuation analysis of Bone Biologics Corp helps investors to measure Bone Biologics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
1.52
Please note that Bone Biologics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Bone Biologics Corp is based on 3 months time horizon. Increasing Bone Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Bone Biologics Corp is useful when determining the fair value of the Bone stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Bone Biologics. Since Bone Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bone Stock. However, Bone Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.52 Real  1.48 Hype  1.52 Naive  1.22
The real value of Bone Stock, also known as its intrinsic value, is the underlying worth of Bone Biologics Corp Company, which is reflected in its stock price. It is based on Bone Biologics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Bone Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bone Biologics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
1.48
Real Value
8.26
Upside
Estimating the potential upside or downside of Bone Biologics Corp helps investors to forecast how Bone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bone Biologics more accurately as focusing exclusively on Bone Biologics' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.291.762.23
Details
Hype
Prediction
LowEstimatedHigh
0.081.528.30
Details
Naive
Forecast
LowNext ValueHigh
0.021.228.00
Details

Bone Biologics Corp Company Current Valuation Analysis

Bone Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Bone Biologics Current Valuation

    
  (1.62 M)  
Most of Bone Biologics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bone Biologics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Bone Biologics Corp has a Current Valuation of (1.62 Million). This is 100.01% lower than that of the Health Care Equipment & Supplies sector and 100.01% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.01% higher than that of the company.

Bone Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bone Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bone Biologics could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics of similar companies.
Bone Biologics is currently under evaluation in current valuation category among related companies.

Bone Fundamentals

About Bone Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:
Check out Bone Biologics Piotroski F Score and Bone Biologics Altman Z Score analysis.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Bone Stock analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.